Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus CEPHALOTHIN SODIUM W DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus CEPHALOTHIN SODIUM W DEXTROSE IN PLASTIC CONTAINER.
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER vs CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Cephalothin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has bactericidal activity against susceptible gram-positive and some gram-negative bacteria.
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
30-60 minutes in normal renal function; prolonged to 2-8 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Primarily renal (60-70% unchanged) via glomerular filtration and tubular secretion; minor biliary (5-10%) and fecal (<1%) elimination.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic